Impact of Device Free Summer Camp on Adolescent Mental Health and Wellbeing

August 19, 2026 updated by: Sapien Labs

IMPACT OF DEVICE FREE SUMMER CAMP ON ADOLESCENT MENTAL HEALTH AND WELLBEING

The goal of this clinical trial is to understand if attendance of a device-free summer camp, representing a shift from a digital environment to one that is device free and involves in person social interaction, can change mental health status and brain physiology in teens age 12-17. The main question it aims to answer is:

  • How much is aggregate mental health and its various dimensions and components changed at the end of the camp attendance relative to the start of camp.
  • How much is brain physiology, as measured by EEG change, changed at the end of camp relative to the start of camp.

Participants are recruited from among teens signed up to attend 2 or 3.5 week sessions a summer camp in Maine.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The goal of this clinical trial is to understand if attendance of a device-free summer camp, representing a shift from a digital environment to one that is device free and involves in person social interaction, can change mental health status and brain physiology in teens age 12-17. The main question it aims to answer is:

  • How much is aggregate mental health and its various dimensions and components changed at the end of the camp attendance relative to the start of camp.
  • How much is brain physiology, as measured by EEG change, changed at the end of camp relative to the start of camp.

Participants are recruited from among teens signed up to attend 2 or 3.5 week sessions a summer camp in Maine. Participants were asked to complete the MHQ, a comprehensive mental health assessment spanning 47 emotional, social and cognitive aspects and on the first day of camp and then again on the day before departure. In addition participants were asked questions on their school and camp experiences at the start and end of camp respectively.

Participants were also invited to participate in a socio-emotional task and/or have EEG measurements read on the first day of camp and the day before departure form camp. The socio-emotional task involved speaking or performing in front of a group of 4 or 5 people and rating one's own feelings performing this task as well as rating the perceived feelings of other group members when they were performing the task.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
333

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Maine
      • Porter, Maine, United States, 04068
        • Maine Teen Camp

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Attendance of Maine Teen Camp sessions during summer months of 2024 and 2025.

Exclusion Criteria:

  • None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Maine Teen Camp attendees
Attendance of a residential device-free summer camp for teens for 2 to 3.5 weeks characterized by in-person interaction and nature rich outdoor activities.
Other: Attendance of device-free summer camp
Attendance of a residential device-free summer camp in Maine for 2-3.5 weeks.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change from Baseline in Mental Health Quotient (MHQ) at End of Camp
Time Frame: Baseline (Day 1) to end of camp attendance (up to 3.5 weeks).
The Mental Health Quotient or MHQ is an aggregate score of mental health computed from the 47 items of the MHQ assessment. The score ranges from -100 to +200, where higher scores indicate better mental health outcomes. Negative scores indicate significant symptoms that impact function (Distressed/Struggling range), while positive scores reflect the wide range of normal function (Enduring to Thriving). Change is calculated by subtracting the baseline score from the end of camp score.
Baseline (Day 1) to end of camp attendance (up to 3.5 weeks).

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change from Baseline in Ratings of 47 MHQ Items After Camp Attendance
Time Frame: Baseline (Day 1) to end of camp attendance (up to 3.5 weeks).
Difference in the ratings of each of the 47 items in the MHQ assessment spanning emotional, social, cognitive and physical capacities and problems. Participants rate each item on a 9-point life impact scale.
Baseline (Day 1) to end of camp attendance (up to 3.5 weeks).
Change from Baseline in Resting-State Electroencephalography (EEG) measures
Time Frame: Baseline (Day 1 of camp) and Post-Intervention (Final day of camp - 2.5-3 weeks later)
The outcome measure evaluates changes in EEG spectral metrics such as spectral slope, spectral bands and time domain metrics such as complexity/entropy measures such as Detrending Fluctuation Analysis (DFA), Lempel-Ziv Complexity and Sample Entropy measured during 3 minutes of EEG with eyes closed at the start and end of the camp session.
Baseline (Day 1 of camp) and Post-Intervention (Final day of camp - 2.5-3 weeks later)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Sapien Labs

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
University of California, San Diego
Rady Children's Hospital, San Diego

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Tara Thiagarajan, PhD, Sapien Labs

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 1, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 17, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 17, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 6, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 11, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 12, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 21, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 19, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • MTC_24_25

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Anonymized assessment and questionnaire responses and raw EEG files

IPD Sharing Time Frame

August 2026 onwards (no end date)

IPD Sharing Access Criteria

Any researcher with stated legitimate research intent will be able to access the anonymized date and supporting information upon submitting an email request to the PI.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings